Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss follicular lymphoma data from ASH 2024.
Samuel Yamshon, MD
Advertisement
Samuel Yamshon, MD, is an assistant professor in the Department of Medicine at NYU Grossman School of Medicine, as well as the medical director of the Cellular Therapy Service at NYU Langone Health in New York, New York.
Articles by Samuel Yamshon, MD
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss data for mosunetuzumab in newly diagnosed follicular lymphoma.
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss 2-year follow-up data for liso-cel in relapsed/refractory follicular lymphoma.
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss CD19 expression and the use of tafasitamab in relapsed/refractory DLBCL.
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss their clinical practice experience using tafasitamab in relapsed/refractory DLBCL.
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss data for tafasitamab in relapsed/refractory follicular lymphoma.
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, break down the current treatment landscape for relapsed/refractory follicular lymphoma.
Samuel Yamshon, MD, of Weill Cornell Medicine/NewYork-Presbyterian, discusses strategies to improve CAR T-cell durability in patients with non-Hodgkin lymphoma.
Advertisement
Latest Updated Articles
Dissecting the Current Treatment Landscape for R/R Follicular LymphomaPublished: December 20th 2024 | Updated:
Strategies to Improve CAR T-cell Durability in LymphomaPublished: May 15th 2024 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma
5